# Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents

> **NCT01407978** · NA · COMPLETED · sponsor: **Fluart Innovative Vaccine Ltd, Hungary** · enrollment: 58 (actual)

## Conditions studied

- Novel 2009 Influenza H1N1
- Influenza, Human

## Interventions

- **BIOLOGICAL:** Vaccination with Fluval P monovalent influenza vaccine
- **BIOLOGICAL:** Vaccination with Fluval AB
- **BIOLOGICAL:** Vaccination with Fluval AB Novo

## Key facts

- **NCT ID:** NCT01407978
- **Lead sponsor:** Fluart Innovative Vaccine Ltd, Hungary
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01407978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01407978, "Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01407978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*